MeaCor is a medical device company focused on developing a transcatheter heart valve repair technology called the CryoCinch system. This minimally invasive system aims to provide a new treatment option for patients suffering from mitral and tricuspid valve regurgitation, a condition where the valves leak blood backward, eventually leading to heart failure.
The CryoCinch system utilizes a novel cryoadhesion technique to address cardiac motion, allowing for the precise and reproducible placement of interconnected anchors along the valve annulus. This technology replicates the gold standard surgical procedure of annuloplasty, where anchors are inserted around the valve annulus and cinched by a wire, effectively halting regurgitation.
The CryoCinch system offers several advantages over conventional open-heart surgery, including shorter recovery times, reduced risks of complications, and lower costs. The procedure involves positioning the catheter, applying cryoadhesion to anchor the device, and cinching the anchors in place, mimicking the suture strength of surgical repairs.
The system's unique features include a 15Fr steerable sheath with thin walls to minimize trauma and complications, a two-step approach with reversible anchor placement for a shorter procedure duration, and robust longitudinal anchors that avoid interference with subannular structures, leaving minimal hardware in the atrium. As of May 2024, MeaCor secured USD 15 million in Series A funding to advance the development of the CryoCinch system.
In May 2022, MeaCor acquired the rights to a novel transcatheter mitral valve repair technology from Edwards Lifesciences, further expanding its product portfolio in the cardiovascular space.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.